Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Markel, Gal ^a,b   Seidman, Rachel ^a   Besser, Michal J ^a   Zabari, Naama ^a   Ortenberg, Rona ^a   Shapira, Ronnie ^a   Treves, Avraham J ^a   Loewenthal, Ron ^a   Orenstein, Arie ^a   Nagler, Arnon ^a   Schachter, Jacob ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER LYSIS RECEPTOR; PROTEIN P30; PROTEIN P46; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CONTROLLED STUDY; DONOR SELECTION; GENE EXPRESSION PROFILING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MELANOMA CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHENOTYPE; SOLID TUMOR; TUMOR CELL DESTRUCTION; FLOW CYTOMETRY; IMMUNOLOGY; KINETICS; MELANOMA; METABOLISM; NATURAL KILLER CELL; TUMOR CELL CULTURE;

FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; KINETICS; MELANOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR; TUMOR CELLS, CULTURED;

EID: 65949111524     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005597     Document Type: Article

References (42)

1. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, et al. (2006) Surface NK receptors and their ligands on tumor cells. Semin Immunol 18: 151-158.
2. Hamerman JA, Ogasawara K, Lanier LL (2005) NK cells in innate immunity. Curr Opin Immunol 17: 29-35.
3. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17: 189-220.
4. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23: 225-74.
5. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9: 503-510.
6. Long EO (1999) Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 17: 875-904.
7. Parham P (2006) Taking license with natural killer cell maturation and repertoire development. Immunol Rev 214: 155-160.
8. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, et al. (2005) A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105: 4416-4423.
9. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, et al. (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25: 331-342.
10. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, et al. (2007) A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110: 578-586.
11. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, et al. (2002) CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 168: 2803-2810.
12. Cantoni C, Bottino C, Augugliaro R, Morelli L, Marcenaro E, et al. (1999) Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol 29: 3148-3159.
13. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, et al. (1998) Molecular cloning of NKp46: novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188: 953-960.
14. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, et al. (1999) NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 189: 787-796.
15. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, et al. (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190: 1505-1516.
16. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
17. Mandelboim O, Malik P, Davis DM, Chang HJ, Boyson JE, et al. (1999) Human CD16 as a lysis receptor mediating direct natural killer (NK) cell cytotoxicity. Proc Natl Acad Sci USA 96: 5640-5644.
18. González S, López-Soto A, Suarez-Alvarez B, López-Vázquez A, López-Larrea C (2008) NKG2D ligands: key targets of the immune response. Trends Immunol 29: 397-403.
19. van de Griend RJ, Bolhuis RL, Stoter G, Roozemond RC (1987) Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. J Immunol 138: 3137-3144.
20. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, et al. (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409: 1055-1060.
21. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, et al. (2001) Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 31: 2680-2689.
22. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, et al. (2005) Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 6: 515-523.
23. Yano T, Sugio K, Yamazaki K, Kase S, Yamaguchi M, et al. (1999) Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer 26: 143-148.
24. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, et al. (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76: 824-832.
25. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, et al. (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339.
26. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
27. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, et al. (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110: 433-440.
28. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, et al. (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104: 170-177.
29. Frohn C, Doehn C, Durek C, Böhle A, Schlenke P, et al. (2000) Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma. J Immunother 23: 499-504.
30. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105: 3051-3057.
31. National Cancer Institute, Surveillance Epidemiology and End Results. http://seer.cancer.gov/csr/1975_2004/results_merged/sect_16_melanoma.pdf.
32. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351: 998-1012.
33. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
34. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
35. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. (2008) Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. J Clin Oncol 26: 5233-5239.
36. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, et al. (2006) Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol 177: 6062-6071.
37. Markel G, Seidman R, Cohen Y, Besser MJ, Cohen Sinai T, et al. (2008) Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 126: 186-200.
38. Dudley ME, Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34: 524-31.
39. Pascal V, Schleinitz N, Brunet C, Ravet S, Bonnet E, et al. (2004) Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions. Eur J Immunol 34: 2930-2940.
40. Schwartz RN, Stover L, Dutcher J (2002) Managing toxicities of high-dose interleukin-2. Oncology 16(11 Suppl 13): 11-20.
41. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, et al. (2005) Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 105: 3615-2622.
42. Vitale C, Chiossone L, Morreale G, Lanino E, Cottalasso F, et al. (2005) Human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation: analysis of the surface expression and function of activating NK receptors. Mol Immunol 42: 405-411.